Systematic review: The epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 40, Issue 1, 2014, Pages 3-15

  Gizard, E ^a   Ford, A C ^b   Bronowicki, J P ^a   Peyrin Biroulet, L ^a  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; HEPARIN;

AMYLOIDOSIS; CHOLELITHIASIS; CORTICOSTEROID THERAPY; CROHN DISEASE; DISEASE ASSOCIATION; FATTY LIVER; GALLBLADDER CARCINOMA; GALLSTONE; HEPATOBILIARY DISEASE; HUMAN; INFLAMMATORY BOWEL DISEASE; LIVER ABSCESS; LIVER AMYLOIDOSIS; PORTAL VEIN THROMBOSIS; PREVALENCE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROCTOCOLECTOMY; REVIEW; RISK FACTOR; SEX DIFFERENCE; SYSTEMATIC REVIEW; ULCERATIVE COLITIS;

BILIARY TRACT DISEASES; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; HUMANS; LIVER DISEASES; MALE; PREVALENCE; RISK; SEX FACTORS;

EID: 84902075780     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12794     Document Type: Review

References (167)

1. Peyrin-Biroulet L, Loftus EV Jr, Colombel J-F, Sandborn WJ,. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol 2010; 105: 289-97.
2. Venkatesh PGK, Navaneethan U, Shen B,. Hepatobiliary disorders and complications of inflammatory bowel disease. Journal of Digestive Diseases 2011; 12: 245-56.
3. Navaneethan U, Shen B,. Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease. Inflamm Bowel Dis 2010; 16: 1598-619.
4. Lin MV, Blonski W, Buchner A, et al,. The influence of anti-TNF therapy on the course of chronic hepatitis C virus infection in patients with inflammatory bowel disease. Dig Dis Sci 2013; 58: 1149-56.
5. Katsanos KH, Tsianos VE, Zois CD, et al,. Inflammatory bowel disease and hepatitis B and C in Western Balkans: a referral centre study and review of the literature. J Crohns Colitis 2010; 4: 450-65.
6. Gisbert JP, Chaparro M, Esteve M,. Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011; 33: 619-33.
7. Khan N, Abbas AM, Whang N, Balart LA, Bazzano LA, Kelly TN,. Incidence of liver toxicity in inflammatory bowel disease patients treated with methotrexate: a meta-analysis of clinical trials. Inflamm Bowel Dis 2012; 18: 359-67.
8. Cassaday RD, Malik JT, Chang JE,. Regression of Hodgkin lymphoma after discontinuation of a tumor necrosis factor inhibitor for Crohn's disease: a case report and review of the literature. Clin Lymphoma Myeloma Leuk 2011; 11: 289-92.
9. Morisco F, Castiglione F, Rispo A, et al,. Hepatitis B virus infection and immunosuppressive therapy in patients with inflammatory bowel disease. Dig Liver Dis 2011; 43 (Suppl. 1): S40-8.
10. Thai A, Prindiville T,. Hepatosplenic T-cell lymphoma and inflammatory bowel disease. J Crohns Colitis 2010; 4: 511-22.
11. Miehsler W, Novacek G, Wenzl H, et al,. A decade of infliximab: the Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. J Crohns Colitis 2010; 4: 221-56.
12. Kotlyar DS, Osterman MT, Diamond RH, et al,. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011; 9: 36-41.
13. Coffin CS, Fraser HF, Panaccione R, Ghosh S,. Liver diseases associated with anti-tumor necrosis factor-alpha (TNF-α) use for inflammatory bowel disease. Inflamm Bowel Dis 2011; 17: 479-84.
14. Flegal KM, Carroll MD, Ogden CL, Curtin LR,. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010; 303: 235-41.
15. Ogden CL, Carroll MD, Kit BK, Flegal KM,. Prevalence of obesity in the United States, 2009-2010. NCHS Data Brief 2012; 1-8.
16. Steed H, Walsh S, Reynolds N,. A brief report of the epidemiology of obesity in the inflammatory bowel disease population of Tayside, Scotland. Obes Facts 2009; 2: 370-2.
17. Dave M, Elmunzer BJ, Dwamena BA, Higgins PD,. Primary sclerosing cholangitis: meta-analysis of diagnostic performance of MR cholangiopancreatography. Radiology 2010; 256: 387-96.
18. Cohen S, Kpplan M, Gottlieb L, Patterson J,. Liver disease and gallstones in regional enteritis. Gastroenterology 1971; 60: 237-45.
19. Parente F, Pastore L, Bargiggia S, et al,. Incidence and risk factors for gallstones in patients with inflammatory bowel disease: a large case-control study. Hepatology 2007; 45: 1267-74.
20. Morsy KH, Hasanain AFA,. Hepatobiliary disorders among naïve patients with ulcerative colitis in Upper Egypt. Arab J Gastroenterol 2012; 13: 71-6.
21. Kratzer W, Haenle MM, Mason RA, von Tirpitz C, Kaechele V,. Prevalence of cholelithiasis in patients with chronic inflammatory bowel disease. World J Gastroenterol 2005; 11: 6170.
22. Lapidus A, Bångstad M, Aström M, Muhrbeck O,. The prevalence of gallstone disease in a defined cohort of patients with Crohn's disease. Am J Gastroenterol 1999; 94: 1261-6.
23. Bargiggia S, Maconi G, Elli M,. Sonographic prevalence of liver steatosis and biliary tract stones in patients with inflammatory bowel disease: study of 511 subjects at a single center. J Clin Gastroenterol 2003; 36: 417-20.
24. Fraquelli M, Losco A, Visentin S, et al,. Gallstone disease and related risk factors in patients with Crohn disease: analysis of 330 consecutive cases. Arch Intern Med 2001; 161: 2201-4.
25. Lorusso D, Leo S, Mossa A, Misciagna G, Guerra V,. Cholelithiasis in inflammatory bowel disease. A case-control study. Dis Colon Rectum 1990; 33: 791-4.
26. Kangas E, Lehmusto P, Matikainen M,. Gallstones in Crohn's disease. Hepatogastroenterology 1990; 37: 83-4.
27. Andersson H, Bosaeus I, Fasth S, Hellberg R, Hultén L,. Cholelithiasis and urolithiasis in Crohn's disease. Scand J Gastroenterol 1987; 22: 253-6.
28. Whorwell PJ, Hawkins R, Dewbury K, Wright R,. Ultrasound survey of gallstones and other hepatobiliary disorders in patients with Crohn's disease. Dig Dis Sci 1984; 29: 930-3.
29. Bluth EI, Merritt CR, Sullivan MA, Kurchin A, Ray JE,. Inflammatory bowel disease and cholelithiasis: the association in patients with an ileostomy. South Med J 1984; 77: 690-2.
30. Baker AL, Kaplan MM, Norton RA, Patterson JF,. Gallstones in inflammatory bowel disease. Am J Dig Dis 1974; 19: 109-12.
31. Marks JW, Conley DR, Capretta TL, et al,. Gallstone prevalence and biliary lipid composition in inflammatory bowel disease. Am J Dig Dis 1977; 22: 1097-100.
32. Hutchinson R, Tyrrell PN, Kumar D, Dunn JA, Li JK, Allan RN,. Pathogenesis of gall stones in Crohn's disease: an alternative explanation. Gut 1994; 35: 94-7.
33. Harvey PR, McLeod RS, Cohen Z, Strasberg SM,. Effect of colectomy on bile composition, cholesterol crystal formation, and gallstones in patients with ulcerative colitis. Ann Surg 1991; 214: 396.
34. Akerlund JE, Einarsson C,. Effects of colectomy on bile composition, cholesterol saturation and cholesterol crystal formation in humans. Int J Colorectal Dis 2000; 15: 248-52.
35. Lapidus A, Einarsson C,. Bile composition in patients with ileal resection due to Crohn's disease. Inflamm Bowel Dis 1998; 4: 89-94.
36. Lapidus A, Einarsson K,. Effects of ileal resection on biliary lipids and bile acid composition in patients with Crohn's disease. Gut 1991; 32: 1488-91.
37. Lapidus A, Akerlund JE, Einarsson C,. Gallbladder bile composition in patients with Crohn's disease. World J Gastroenterol 2006; 12: 70.
38. Pereira SP, Bain IM, Kumar D, Dowling RH,. Bile composition in inflammatory bowel disease: ileal disease and colectomy, but not colitis, induce lithogenic bile. Aliment Pharmacol Ther 2003; 17: 923-33.
39. Rutgeerts P, Ghoos Y, Vantrappen G, Fevery J., Biliary lipid composition in patients with nonoperated Crohn's disease. Dig Dis Sci 1986; 31: 27-32.
40. Brink MA, Slors JF, Keulemans YC, et al,. Enterohepatic cycling of bilirubin: a putative mechanism for pigment gallstone formation in ileal Crohn's disease. Gastroenterology 1999; 116: 1420-7.
41. Murray FE, McNicholas M, Stack W, O'Donoghue DP,. Impaired fatty-meal-stimulated gallbladder contractility in patients with Crohn's disease. Clin Sci 1992; 83: 689-93.
42. Annese V, Vantrappen G,. Gall stones in Crohn's disease: another hypothesis. Gut 1994; 35: 1676.
43. Damião AO, Sipahi AM, Vezozzo DP, Gonçalves PL, Fukui P, Laudanna AA,. Gallbladder hypokinesia in Crohn's disease. Digestion 1997; 58: 458-63.
44. Toelen C, Huyghe M,. Gallstone ileus in a patient with Crohn's disease: a case report. Acta Chir Belg 2012; 112: 390-2.
45. Basili G, Lorenzetti L, Celona G, et al,. Gallstone ileus in patient with Crohn's disease: report of a clinical observation. Surg Endosc 2006; 20: 703-4.
46. La Meir M, Van Molhem Y,. Recurrence of gallstone ileus with Crohn's disease. Acta Chir Belg 2001; 101: 35-7.
47. Almogy G, Bauer JJ, Venturero M, Presen DH,. Gallstone ileus and Crohn's disease without biliary-enteric fistula: report of a unique case. Mt Sinai J Med 2000; 67: 159-62.
48. Senofsky GM, Stabile BE,. Gallstone ileus associated with Crohn's disease. Surgery 1990; 108: 114-7.
49. Highman L, Jagelman DG,. Gallstone ileus complicating terminal ileal Crohn's disease. Br J Surg 1981; 68: 201-2.
50. Rudolph G, Gotthardt D, Kloeters-Plachky P, Rost D, Kulaksiz H, Stiehl A,. In PSC with dominant bile duct stenosis, IBD is associated with an increase of carcinomas and reduced survival. J Hepatol 2010; 53: 313-7.
51. Dorudi S, Chapman RW, Kettlewell MG,. Carcinoma of the gallbladder in ulcerative colitis and primary sclerosing cholangitis. Report of two cases. Dis Colon Rectum 1991; 34: 827-8.
52. Joffe N, Antonioli DA,. Primary carcinoma of the gallbladder associated with chronic inflammatory bowel disease. Clin Radiol 1981; 32: 319-24.
53. Noda H, Chiba F, Toyama N, Konishi F,. Mucin-producing carcinoma of the gallbladder associated with primary sclerosing cholangitis and ulcerative colitis. J Hepato-Biliary-Pancreat Surg 2008; 16: 83-5.
54. O'Connor R, Harding B, Greene D, Coolican J,. Primary carcinoma of the gall bladder associated with ulcerative colitis. Postgrad Med J 1986; 62: 871-2.
55. Ogawa H, Funayama Y, Naito H, et al,. Gallbladder carcinoma complicating Crohn's disease. Am J Gastroenterol 2001; 96: 263-4.
56. Yamamoto T, Uki K, Takeuchi K,. Early gallbladder carcinoma associated with primary sclerosing cholangitis and ulcerative colitis. J Gastroenterol 2003; 38: 704-6.
57. Smith MP, Loe RH., Sclerosing cholangitis; review of recent case reports and associated diseases and four new cases. Am J Surg 1965; 110: 239-46.
58. Thorpe M, Scheuer PJ, Sherlock S,. Primary sclerosing cholangitis, the biliary tree, and ulcerative colitis. Gut 1967; 8: 435-48.
59. Rasmussen HH, Fallingborg JF, Mortensen PB, Vyberg M, Tage-Jensen U, Rasmussen SN,. Hepatobiliary dysfunction and primary sclerosing cholangitis in patients with Crohn's disease. Scand J Gastroenterol 1997; 32: 604-10.
60. Aitola P, Karvonen AL, Matikainen M,. Prevalence of hepatobiliary dysfunction in patients with ulcerative colitis. Ann Chir Gynaecol 1994; 83: 275-8.
61. Broomé U, Glaumann H, Hellers G, Nilsson B, Sörstad J, Hultcrantz R, Liver disease in ulcerative colitis: an epidemiological and follow up study in the county of Stockholm. Gut 1994; 35: 84-9.
62. Broomé U, Glaumann H, Hultcrantz R,. Liver histology and follow up of 68 patients with ulcerative colitis and normal liver function tests. Gut 1990; 31: 468-72.
63. Lupinetti M, Mehigan D, Cameron JL,. Hepatobiliary complications of ulcerative colitis. The American Journal of Surgery 1980; 139: 113-8.
64. Olsson R, Danielsson A, Järnerot G, et al,. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology 1991; 100: 1319-23.
65. Rasmussen HH, Fallingborg J, Mortensen PB, et al,. Primary sclerosing cholangitis in patients with ulcerative colitis. Scand J Gastroenterol 1992; 27: 732-6.
66. Schrumpf E, Fausa O, Kolmannskog F, Elgjo K, Ritland S, Gjone E,. Sclerosing cholangitis in ulcerative colitis. A follow-up study. Scand J Gastroenterol 1982; 17: 33-9.
67. Shepherd HA, Selby WS, Chapman RW, et al,. Ulcerative colitis and persistent liver dysfunction. Q J Med 1983; 52: 503-13.
68. Hashimoto E, Ideta M, Taniai M, et al,. Prevalence of primary sclerosing cholangitis and other liver diseases in Japanese patients with chronic ulcerative colitis. J Gastroenterol Hepatol 1993; 8: 146-9.
69. Bernstein CN, Blanchard JF, Rawsthorne P, Yu N., The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 2001; 96: 1116-22.
70. Nemeth A, Ejderhamn J, Glaumann H, Strandvik B,. Liver damage in juvenile inflammatory bowel disease. Liver 1990; 10: 239-48.
71. Tobias R, Wright JP, Kottler RE, et al,. Primary sclerosing cholangitis associated with inflammatory bowel disease in Cape Town, 1975-1981. S Afr Med J 1983; 63: 229-35.
72. Wewer V, Gluud C, Schlichting P, Burcharth F, Binder V,. Prevalence of hepatobiliary dysfunction in a regional group of patients with chronic inflammatory bowel disease. Scand J Gastroenterol 1991; 26: 97-102.
73. Halliday JS, Djordjevic J, Lust M, et al,. A unique clinical phenotype of primary sclerosing cholangitis associated with Crohn's disease. J Crohns Colitis 2012; 6: 174-81.
74. Joo M, Abreu-e-Lima P, Farraye F, et al,. Pathologic features of ulcerative colitis in patients with primary sclerosing cholangitis: a case-control study. The American journal of surgical pathology 2009; 33: 854-62.
75. Sinakos E, Samuel S, Enders F, Loftus EV Jr, Sandborn WJ, Lindor KD,. Inflammatory bowel disease in primary sclerosing cholangitis: a robust yet changing relationship. Inflamm Bowel Dis 2013; 19: 1004-9.
76. Seibold F, Weber P, Klein R, Berg PA, Wiedmann KH,. Clinical significance of antibodies against neutrophils in patients with inflammatory bowel disease and primary sclerosing cholangitis. Gut 1992; 33: 657-62.
77. Bansi DS, Fleming KA, Chapman RW,. Importance of antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and ulcerative colitis: prevalence, titre, and IgG subclass. Gut 1996; 38: 384-9.
78. Claise C, Johanet C, Bouhnik Y, Kapel N, Homberg JC, Poupon R,. Antineutrophil cytoplasmic autoantibodies in autoimmune liver and inflammatory bowel diseases. Liver 1996; 16: 28-34.
79. Lundqvist K, Broomé U,. Differences in colonic disease activity in patients with ulcerative colitis with and without primary sclerosing cholangitis: a case control study. Dis Colon Rectum 1997; 40: 451-6.
80. Moayyeri A, Daryani NE, Bahrami H, Haghpanah B, Nayyer-Habibi A, Sadatsafavi M,. Clinical course of ulcerative colitis in patients with and without primary sclerosing cholangitis. J Gastroenterol Hepatol 2005; 20: 366-70.
81. Oshitani N, Jinno Y, Sawa Y, et al,. Does colitis associated with primary sclerosing cholangitis represent an actual subset of ulcerative colitis? Hepatogastroenterology 2003; 50: 1830-5.
82. Sokol H, Cosnes J, Chazouilleres O, et al,. Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis. World J Gastroenterol 2008; 14: 3497-503.
83. Boonstra K, Beuers U, Ponsioen CY,. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol 2012; 56: 1181-8.
84. Marelli L, Xirouchakis E, Kalambokis G, Cholongitas E, Hamilton MI, Burroughs AK,. Does the severity of primary sclerosing cholangitis influence the clinical course of associated ulcerative colitis? Gut 2011; 60: 1224-8.
85. Navaneethan U, Venkatesh PG, Mukewar S, et al,. Progressive primary sclerosing cholangitis requiring liver transplantation is associated with reduced need for colectomy in patients with ulcerative colitis. Clin Gastroenterol Hepatol 2012; 10: 540-6.
86. Loftus EV Jr, Harewood GC, Loftus CG, et al,. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005; 54: 91-6.
87. Cangemi JR, Wiesner RH, Beaver SJ, et al,. Effect of proctocolectomy for chronic ulcerative colitis on the natural history of primary sclerosing cholangitis. Gastroenterology 1989; 96: 790-4.
88. Alabraba E, Nightingale P, Gunson B, et al,. A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts. Liver Transpl 2009; 15: 330-40.
89. Vera A, Moledina S, Gunson B, et al,. Risk factors for recurrence of primary sclerosing cholangitis of liver allograft. Lancet 2002; 360: 1943-4.
90. Thomas C,. Ulceration of the colon with a much enlarged fatty liver. Trans Path Soc Philadelphia 1874; 4: 87-8.
91. Ross JR, Swarts JM,. Hepatic dysfunction and cirrhosis in chronic ulcerative colitis. Gastroenterology 1948; 10: 81-95.
92. Pollard HM, Block M,. Association of hepatic insufficiency with chronic ulcerative colitis. Arch Intern Med (Chic) 1948; 82: 159-74.
93. Dyson FL,. Liver damage in ulcerative colitis. Br Med J 1950; 1: 1301.
94. Jones GW, Baggenstoss AH, Bargen JA., Hepatic lesions and dysfunction associated with chronic ulcerative colitis. Am J Med Sci 1951; 221: 279-86.
95. Kleckner MS Jr, Stauffer MH, Bargen JA, Dockerty MB,. Hepatic lesions in the living patient with chronic ulcerative colitis as demonstrated by needle biopsy. Gastroenterology 1952; 22: 13-33.
96. Chapin LE, Scudamore HH, Baggenstoss AH, Bargen JA,. Regional enteritis: associated visceral changes. Gastroenterology 1956; 30: 404-15.
97. Monto AS,. The liver in ulcerative disease of the intestinal tract: functional and anatomic changes. Ann Intern Med 1959; 50: 1385-94.
98. Palmer WL, Kirsner JB, Goldgraber MB, Fuentes SS,. Disease of the liver in chronic ulcerative colitis. Am J Med 1964; 36: 856-66.
99. De Dombal FT, Goldie W, Watts JM, Goligher JC,. Hepatic histological changes in ulcerative colitis. A series of 58 consecutive operative liver biopsies. Scand J Gastroenterol 1966; 1: 220-7.
100. Dordal E, Glagov S, Kirsner JB,. Hepatic lesions in chronic inflammatory bowel disease. I. Clinical correlations with liver biopsy diagnoses in 103 patients. Gastroenterology 1967; 52: 239-53.
101. Perrett AD, Higgins G, Johnston HH, Massarella GR, Truelove SC, Wright R,. The liver in ulcerative colitis. Q J Med 1971; 40: 211-38.
102. Perrett AD, Higgins G, Johnston HH, Massarella GR, Truelove SC, Wrigth R,. The liver in Crohn's disease. Q J Med 1971; 40: 187-209.
103. Gisbert JP, Luna M, González-Lama Y, et al,. Liver injury in inflammatory bowel disease: long-term follow-up study of 786 patients. Inflamm Bowel Dis 2007; 13: 1106-14.
104. Kimmelstiel P, Large HL Jr, Verner HD,. Liver damage in ulcerative colitis. Am J Pathol 1952; 28: 259-89.
105. Warren S, Sommers SC,. Pathogenesis of ulcerative colitis. Am J Pathol 1949; 25: 657-79.
106. Parker RG, Kendall EJ,. The liver in ulcerative colitis. Br Med J 1954; 2: 1030-2.
107. Eade MN,. Liver disease in ulcerative colitis. I. Analysis of operative liver biopsy in 138 consecutive patients having colectomy. Ann Intern Med 1970; 72: 475-87.
108. Mattila J, Aitola P, Matikainen M,. Liver lesions found at colectomy in ulcerative colitis: correlation between histological findings and biochemical parameters. J Clin Pathol 1994; 47: 1019-21.
109. Scalone O, Bonaventure C, Pasquier D, Faucheron JL,. Should liver biopsy be systematic during surgery for ulcerative colitis? Gastroenterol Clin Biol 2003; 27: 94-9.
110. Yamamoto-Furusho JK, Sánchez-Osorio M, Uribe M,. Prevalence and factors associated with the presence of abnormal function liver tests in patients with ulcerative colitis. Ann Hepatol 2010; 9: 397-401.
111. Riegler G, D'Incà R, Sturniolo GC, et al,. Hepatobiliary alterations in patients with inflammatory bowel disease: a multicenter study. Caprilli & Gruppo Italiano Studio Colon-Retto. Scand J Gastroenterol 1998; 33: 93-8.
112. Mendes FD, Levy C, Enders FB, Loftus EV Jr, Angulo P, Lindor KD,. Abnormal hepatic biochemistries in patients with inflammatory bowel disease. Am J Gastroenterol 2007; 102: 344-50.
113. Chalasani N, Younossi Z, Lavine JE, et al,. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142: 1592-609.
114. McGowan CE, Jones P, Long MD, Barritt AS 4th,. Changing shape of disease: nonalcoholic fatty liver disease in Crohn's disease-A case series and review of the literature. Inflamm Bowel Dis 2012; 18: 49-54.
115. Dietrich CF, Schall H, Kirchner J, et al,. Sonographic detection of focal changes in the liver hilus in patients receiving corticosteroid therapy. Z Gastroenterol 1997; 35: 1051-7.
116. Candelli M, Nista EC, Pignataro G, et al,. Steatohepatitis during methylprednisolone therapy for ulcerative colitis exacerbation. J Intern Med 2003; 253: 391-2.
117. Fakhouri TH, Ogden CL, Carroll MD, Kit BK, Flegal KM,. Prevalence of obesity among older adults in the United States, 2007-2010. NCHS Data Brief 2012; 1-8.
118. Ogden CL, Carroll MD, Kit BK, Flegal KM,. Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010. JAMA 2012; 307: 483-90.
119. Long MD, Crandall WV, Leibowitz IH., Prevalence and epidemiology of overweight and obesity in children with inflammatory bowel disease. Inflamm Bowel Dis 2011; 17: 2162-8.
120. Serra I, Oller B, Mañosa M, et al,. Systemic amyloidosis in inflammatory bowel disease: retrospective study on its prevalence, clinical presentation, and outcome. J Crohns Colitis 2010; 4: 269-74.
121. Wester AL, Vatn MH, Fausa O,. Secondary amyloidosis in inflammatory bowel disease: a study of 18 patients admitted to Rikshospitalet University Hospital, Oslo, from 1962 to 1998. Inflamm Bowel Dis 2006; 7: 295-300.
122. Greenstein AJ, Sachar DB, Panday AK, et al,. Amyloidosis and inflammatory bowel disease. A 50-year experience with 25 patients. Medicine (Baltimore) 1992; 71: 261-70.
123. Basturk T, Ozagari A, Ozturk T, Kusaslan R, Unsal A,. Crohn's disease and secondary amyloidosis: early complication? A case report and review of the literature. J Ren Care 2009; 35: 147-50.
124. Gitkind MJ, Wright SC,. Amyloidosis complicating inflammatory bowel disease. Dig Dis Sci 1990; 35: 906-8.
125. Margalit M, Elinav H, Ilan Y, Shalit M,. Liver abscess in inflammatory bowel disease: report of two cases and review of the literature. J Gastroenterol Hepatol 2004; 19: 1338-42.
126. Hazzan D, Fishman E, Heller E, Chapman M, Bauer JJ., Liver abscess in Crohn's disease: a report of three cases. Mt Sinai J Med 2004; 71: 351-4.
127. Mir-Madjlessi SH, McHenry MC, Farmer RG,. Liver abscess in Crohn's disease. Report of four cases and review of the literature. Gastroenterology 1986; 91: 987-93.
128. Remzi FH, Fazio VW, Oncel M, et al,. Portal vein thrombi after restorative proctocolectomy. Surgery 2002; 132: 655-62.
129. Baker ME, Remzi F, Einstein D, et al,. CT depiction of portal vein thrombi after creation of ileal pouch-anal anastomosis. Radiology 2003; 227: 73-9.
130. Ball CG, MacLean AR, Buie WD, et al,. Portal vein thrombi after ileal pouch-anal anastomosis: its incidence and association with pouchitis. Surg Today 2007; 37: 552-7.
131. Bolondi L, Gaiani S, Testa S, Labò G,. Gall bladder sludge formation during prolonged fasting after gastrointestinal tract surgery. Gut 1985; 26: 734-8.
132. Pitt HA, King W 3rd, Mann L, L, et al. Increased risk of cholelithiasis with prolonged total parenteral nutrition. Am J Surg 1983; 145: 106-12.
133. Roslyn JJ, Pitt HA, Mann LL, Ament ME, DenBesten L,. Gallbladder disease in patients on long-term parenteral nutrition. Gastroenterology 1983; 84: 148-54.
134. Naini BV, Lassman CR,. Total parenteral nutrition therapy and liver injury: a histopathologic study with clinical correlation. Hum Pathol 2012; 43: 826-33.
135. Biancone L, Michetti P, Travis S, et al,. European evidence-based Consensus on the management of ulcerative colitis: special situations. J Crohns Colitis 2008; 2: 63-92.
136. Xiao W-B, Liu Y-L,. Primary biliary cirrhosis and ulcerative colitis: a case report and review of literature. World J Gastroenterol 2003; 9: 878-80.
137. Hilzenrat N, Lamoureux E, Sherker A, Cohen A,. Cholestasis in Crohn's disease: a diagnostic challenge. Can J Gastroenterol 1997; 11: 35-7.
138. Tofteland ND, Nassif II,. Abnormal liver enzymes in a patient with Crohn's disease, psoriatic arthritis, and recurrent pancreatitis. Answer to the clinical challenges and images in GI question: image 5: idiopathic granulomatous hepatitis. Gastroenterology 2010; 139: e14-5.
139. Quallich LG, Greenson J, Haftel HM, Fontana RJ,. Is it Crohn's disease? A severe systemic granulomatous reaction to sulfasalazine in patient with rheumatoid arthritis. BMC Gastroenterol 2001; 1: 8.
140. Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D,. Sulfasalazine hepatotoxicity. Am J Gastroenterol 1984; 79: 401-2.
141. Namias A, Bhalotra R, Donowitz M,. Reversible sulfasalazine-induced granulomatous hepatitis. J Clin Gastroenterol 1981; 3: 193-8.
142. Callen JP, Soderstrom RM,. Granulomatous hepatitis associated with salicylazosulfapyridine therapy. South Med J 1978; 71: 1159-60.
143. Braun M, Fraser GM, Kunin M, Salamon F, Tur-Kaspa R,. Mesalamine-induced granulomatous hepatitis. Am J Gastroenterol 1999; 94: 1973-4.
144. Rabinovitz M, Demetris AJ, Bou-Abboud CF, Van Thiel DH,. Simultaneous occurrence of primary sclerosing cholangitis and autoimmune chronic active hepatitis in a patient with ulcerative colitis. Dig Dis Sci 1992; 37: 1606-11.
145. Gohlke F, Lohse AW, Dienes HP, et al,. Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis. J Hepatol 1996; 24: 699-705.
146. Luketic VA, Gomez DA, Sanyal AJ, Shiffman ML,. An atypical presentation for primary sclerosing cholangitis. Dig Dis Sci 1997; 42: 2009-16.
147. McNair AN, Moloney M, Portmann BC, Williams R, McFarlane IG,. Autoimmune hepatitis overlapping with primary sclerosing cholangitis in five cases. Am J Gastroenterol 1998; 93: 777-84.
148. Koskinas J, Raptis I, Manika Z, Hadziyannis S,. Overlapping syndrome of autoimmune hepatitis and primary sclerosing cholangitis associated with pyoderma gangrenosum and ulcerative colitis. Eur J Gastroenterol Hepatol 1999; 11: 1421-4.
149. Domschke W, Klein R, Terracciano LM, et al,. Sequential occurrence of primary sclerosing cholangitis and autoimmune hepatitis type III in a patient with ulcerative colitis: a follow up study over 14 years. Liver 2000; 20: 340-5.
150. van Buuren HR, van Hoogstraten HJE, Terkivatan T, Schalm SW, Vleggaar FP,. High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis. J Hepatol 2000; 33: 543-8.
151. Abdo AA, Bain VG, Kichian K, Lee SS,. Evolution of autoimmune hepatitis to primary sclerosing cholangitis: a sequential syndrome. Hepatology 2002; 36: 1393-9.
152. Floreani A, Rizzotto ER, Ferrara F, et al,. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol 2005; 100: 1516-22.
153. Lucas RG Jr, Lee EY,. Overlapping syndrome of autoimmune hepatitis and primary sclerosing cholangitis associated with ulcerative colitis. Pediatr Radiol 2007; 37: 844.
154. Sander LE, Koch A, Gartung C, et al,. Lessons from a patient with an unusual hepatic overlap syndrome. Nat Clin Pract Gastroenterol Hepatol 2007; 4: 635-40.
155. Malik TA, Gutierrez AM, McGuire B, Zarzour JG, Mukhtar F, Bloomer J., Autoimmune hepatitis-primary sclerosing cholangitis overlap syndrome complicated by Crohn's disease. Digestion 2010; 82: 24-6.
156. Perdigoto R, Carpenter HA, Czaja AJ,. Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis. J Hepatol 1992; 14: 325-31.
157. Gregorio GV, Portmann B, Karani J, et al,. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001; 33: 544-53.
158. Mendes FD, Jorgensen R, Keach J, et al,. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol 2006; 101: 2070-5.
159. Erkelens GW, Vleggaar FP, Lesterhuis W, van Buuren HR, van der Werf SD., Sclerosing pancreato-cholangitis responsive to steroid therapy. Lancet 1999; 354: 43-4.
160. Dastis SN, Latinne D, Sempoux C, Geubel AP,. Ulcerative colitis associated with IgG4 cholangitis: similar features in two HLA identical siblings. J Hepatol 2009; 51: 601-5.
161. Björnsson E, Chari ST, Smyrk TC, Lindor K,. Immunoglobulin G4 associated cholangitis: description of an emerging clinical entity based on review of the literature. Hepatology 2007; 45: 1547-54.
162. Tada F, Abe M, Nunoi H, et al,. Ulcerative colitis complicated with primary biliary cirrhosis. Intern Med 2011; 50: 2323-7.
163. Arai O, Ikeda H, Mouri H, Notohara K, Matsueda K,. Two cases of inflammatory bowel disease diagnosed in the course of primary biliary cirrhosis. Nihon Shokakibyo Gakkai Zasshi 2010; 107: 900-8.
164. Jang HJ, Kim GS, Eun CS, Kae SH, Jang WY, Lee J,. Development of primary biliary cirrhosis in a patient with Crohn's disease: a case report and review of the literature. Dig Dis Sci 2005; 50: 2335-7.
165. Nakayama M, Tsuji H, Shimono J, et al,. Primary biliary cirrhosis associated with ulcerative colitis. Fukuoka Igaku Zasshi 2001; 92: 354-9.
166. Koulentaki M, Koutroubakis IE, Petinaki E, et al,. Ulcerative colitis associated with primary biliary cirrhosis. Dig Dis Sci 1999; 44: 1953-6.
167. Bush A, Mitchison H, Walt R, Baron JH, Boylston AW, Summerfield JA,. Primary biliary cirrhosis and ulcerative colitis. Gastroenterology 1987; 92: 2009-13.